What are the unmet needs in the treatment of NMOSD despite eculizumab?

Mar 18, 2025 ... How is Soliris administered in myasthenia gravis? · 900 mg weekly for the first four weeks · 1,200 mg in the fifth week · 1,200 mg every other ... Indicated for paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Doses 1-4: 600 mg IV qWeek for first 4 weeks, followed by Dose 5: 900 mg IV 1 week ... Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Feb 7, 2024 ... Eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive refractory generalized myasthenia gravis (gMG). Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... What is Eculizumab · It is a monoclonal antibody. · It is used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH) ... Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data. May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ... This medication is given by a healthcare provider as an infusion through the vein to stop the body's immune system from attacking itself. Soliris (eculizumab) ...